PRIVATE EQUITY
US$20 Million Series A Investment in Mirror Biologics
Oct 2022 · Venture Capital · Biotechnology
In October 2022, Bradbury Group finalized a US$20 million investment in Mirror Biologics, Inc., an international clinical-stage biotechnology company. This capital injection marks the final close of the issuer's US$30 million Series A private equity round.
The funding is allocated to support Mirror Biologics' clinical pipeline, specifically advancing its ongoing immunology and oncology clinical trials. Additionally, proceeds from the Series A round are directed toward the expansion of the company's commercial-scale biomanufacturing infrastructure and general corporate working capital.
This transaction aligns with Bradbury's strategic mandate of deploying capital into regulated, mid-to-late-stage life science and biopharma enterprises.